{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:00:19Z","timestamp":1792857619538,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Collaborative Academic Innovation Project of Shandong Cancer Hospital","award":["TS007"],"award-info":[{"award-number":["TS007"]}]},{"name":"the Mount Taishan Scholar Program Special Fund","award":["tsqn202312369"],"award-info":[{"award-number":["tsqn202312369"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-026-06443-7","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:44:08Z","timestamp":1773341048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy in locally advanced resectable esophageal squamous cell carcinoma"],"prefix":"10.1007","volume":"152","author":[{"given":"Yuanyuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiqin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"6443_CR31","unstructured":"Amin MB, Edge SB, Greene FL, et al (eds) (2017) AJCC Cancer Staging Manual, 8th edn. Springer, New York"},{"key":"6443_CR2","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083\u20133107. https:\/\/doi.org\/10.1002\/sim.3697","journal-title":"Stat Med"},{"key":"6443_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"6443_CR4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.arthro.2021.06.037","volume":"38","author":"JW Chen","year":"2022","unstructured":"Chen JW, Maldonado DR, Kowalski BL et al (2022) Best practice guidelines for propensity score methods in medical research: consideration on theory, implementation, and reporting. A review. Arthrosc J Arthrosc Relat Surg 38:632\u2013642. https:\/\/doi.org\/10.1016\/j.arthro.2021.06.037","journal-title":"Arthrosc J Arthrosc Relat Surg"},{"key":"6443_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005830","volume":"11","author":"X Chen","year":"2023","unstructured":"Chen X, Xu X, Wang D et al (2023) Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial. J Immunother Cancer 11:e005830. https:\/\/doi.org\/10.1136\/jitc-2022-005830","journal-title":"J Immunother Cancer"},{"key":"6443_CR6","doi-asserted-by":"publisher","DOI":"10.4324\/9780203771587","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"2013","unstructured":"Cohen J (2013) Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Routledge, New York","edition":"2"},{"key":"6443_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"6443_CR8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","volume":"39","author":"BM Eyck","year":"2021","unstructured":"Eyck BM, Van Lanschot JJB, Hulshof MCCM et al (2021) Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol 39:1995\u20132004. https:\/\/doi.org\/10.1200\/JCO.20.03614","journal-title":"J Clin Oncol"},{"key":"6443_CR9","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2025.0220","volume":"160","author":"X Guo","year":"2025","unstructured":"Guo X, Chen C, Zhao J et al (2025) Neoadjuvant chemoradiotherapy vs chemoimmunotherapy for esophageal squamous cell carcinoma. JAMA Surg 160:565\u2013574. https:\/\/doi.org\/10.1001\/jamasurg.2025.0220","journal-title":"JAMA Surg"},{"key":"6443_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H et al (2024) Cancer incidence and mortality in China, 2022. J Natl Cancer Cent 4:47\u201353. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006","journal-title":"J Natl Cancer Cent"},{"key":"6443_CR11","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/oncolo\/oyab011","volume":"27","author":"W He","year":"2022","unstructured":"He W, Leng X, Mao T et al (2022) Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma. Oncologist 27:e18\u2013e28. https:\/\/doi.org\/10.1093\/oncolo\/oyab011","journal-title":"Oncologist"},{"key":"6443_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, Machida R, Ito Y et al (2024) Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet 404:55\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(24)00745-1","journal-title":"Lancet"},{"key":"6443_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.LBA329","volume":"43","author":"X Leng","year":"2025","unstructured":"Leng X, He W, Lyu J et al (2025) Preliminary results from the multicenter, randomized phase III trial (SCIENCE): comparing chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant treatment in resectable locally advanced esophageal squamous cell carcinoma. J Clin Oncol 43:LBA329. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.LBA329","journal-title":"J Clin Oncol"},{"key":"6443_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejca.2020.08.002","volume":"138","author":"S Liu","year":"2020","unstructured":"Liu S, Wen J, Yang H et al (2020) Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010. Eur J Cancer 138:113\u2013121. https:\/\/doi.org\/10.1016\/j.ejca.2020.08.002","journal-title":"Eur J Cancer"},{"key":"6443_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ijc.33976","volume":"151","author":"J Liu","year":"2022","unstructured":"Liu J, Li J, Lin W et al (2022a) Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study. Int J Cancer 151:128\u2013137. https:\/\/doi.org\/10.1002\/ijc.33976","journal-title":"Int J Cancer"},{"key":"6443_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004291","volume":"10","author":"J Liu","year":"2022","unstructured":"Liu J, Yang Y, Liu Z et al (2022b) Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer 10:e004291. https:\/\/doi.org\/10.1136\/jitc-2021-004291","journal-title":"J Immunother Cancer"},{"key":"6443_CR17","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.1245\/s10434-023-13778-9","volume":"30","author":"F Su","year":"2023","unstructured":"Su F, Yang X, Yin J et al (2023) Validity of using pathological response as a surrogate for overall survival in neoadjuvant studies for esophageal cancer: a systematic review and meta-analysis. Ann Surg Oncol 30:7461\u20137471. https:\/\/doi.org\/10.1245\/s10434-023-13778-9","journal-title":"Ann Surg Oncol"},{"key":"6443_CR18","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.jtcvs.2020.09.042","volume":"162","author":"H Tang","year":"2021","unstructured":"Tang H, Jiang D, Zhang S et al (2021) Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 162:1632\u20131641. https:\/\/doi.org\/10.1016\/j.jtcvs.2020.09.042","journal-title":"J Thorac Cardiovasc Surg"},{"key":"6443_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","volume":"34","author":"H Tang","year":"2023","unstructured":"Tang H, Wang H, Fang Y et al (2023) Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Ann Oncol 34:163\u2013172. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.508","journal-title":"Ann Oncol"},{"key":"6443_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106767","volume":"104","author":"Z Wang","year":"2022","unstructured":"Wang Z, Shao C, Wang Y et al (2022) Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis. Int J Surg 104:106767. https:\/\/doi.org\/10.1016\/j.ijsu.2022.106767","journal-title":"Int J Surg"},{"key":"6443_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12946-8","volume":"24","author":"Y Wang","year":"2024","unstructured":"Wang Y, Ma K, Zhang H et al (2024) Comparison of pathologic response and survival outcomes between neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant immunochemotherapy (nICT) in patients with locally advanced esophageal squamous cell carcinoma: a propensity score-matched analysis. BMC Cancer 24:1228. https:\/\/doi.org\/10.1186\/s12885-024-12946-8","journal-title":"BMC Cancer"},{"key":"6443_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezac341","volume":"62","author":"X Xiao","year":"2022","unstructured":"Xiao X, Yang Y-S, Zeng X-X et al (2022) The comparisons of neoadjuvant chemoimmunotherapy versus chemoradiotherapy for oesophageal squamous cancer. Eur J Cardiothorac Surg 62:ezac341. https:\/\/doi.org\/10.1093\/ejcts\/ezac341","journal-title":"Eur J Cardiothorac Surg"},{"key":"6443_CR23","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/JS9.0000000000000816","volume":"110","author":"J Xu","year":"2023","unstructured":"Xu J, Cai Y, Hong Z et al (2023) Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis. Int J Surg 110:490\u2013506. https:\/\/doi.org\/10.1097\/JS9.0000000000000816","journal-title":"Int J Surg"},{"key":"6443_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003497","volume":"10","author":"W Yang","year":"2022","unstructured":"Yang W, Xing X, Yeung S-CJ et al (2022) Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J Immunother Cancer 10:e003497. https:\/\/doi.org\/10.1136\/jitc-2021-003497","journal-title":"J Immunother Cancer"},{"key":"6443_CR25","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jtcvs.2023.08.056","volume":"167","author":"Y Yang","year":"2024","unstructured":"Yang Y, Liu J, Liu Z et al (2024) Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study. J Thorac Cardiovasc Surg 167:838-847.e1. https:\/\/doi.org\/10.1016\/j.jtcvs.2023.08.056","journal-title":"J Thorac Cardiovasc Surg"},{"key":"6443_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14726-4","volume":"25","author":"Q Yang","year":"2025","unstructured":"Yang Q, Zhou X, Li J et al (2025a) Comparative analysis and optimization of tumor regression grade assessment systems in neoadjuvant therapy for esophageal squamous cell carcinoma. BMC Cancer 25:1341. https:\/\/doi.org\/10.1186\/s12885-025-14726-4","journal-title":"BMC Cancer"},{"key":"6443_CR27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtcvs.2024.06.020","volume":"169","author":"X Yang","year":"2025","unstructured":"Yang X, Yin H, Zhang S et al (2025b) Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 169:289-300.e6. https:\/\/doi.org\/10.1016\/j.jtcvs.2024.06.020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"6443_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jtcvs.2023.12.030","volume":"168","author":"Y Yu","year":"2024","unstructured":"Yu Y, Meng F-Y, Wei X et al (2024) Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 168:417-428.e3. https:\/\/doi.org\/10.1016\/j.jtcvs.2023.12.030","journal-title":"J Thorac Cardiovasc Surg"},{"key":"6443_CR29","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.21037\/atm-21-5381","volume":"9","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Hong Z-N, Xie S et al (2021) Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1). Ann Transl Med 9:1623\u20131623. https:\/\/doi.org\/10.21037\/atm-21-5381","journal-title":"Ann Transl Med"},{"key":"6443_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1031171","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Ye J, Li H et al (2022) Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase 2 trial. Front Immunol 13:1031171. https:\/\/doi.org\/10.3389\/fimmu.2022.1031171","journal-title":"Front Immunol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06443-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06443-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06443-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:44:10Z","timestamp":1773341050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06443-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6443"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06443-7","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Shandong Cancer Hospital and Institute review board (SDTHEC202411010), and the requirement for informed consent was waived due to the retrospective nature of the study. The study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"64"}}